Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Feb;70(2):338-51.
doi: 10.1016/j.jaad.2013.10.010. Epub 2013 Nov 27.

Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis

Affiliations
Review

Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis

Lawrence F Eichenfield et al. J Am Acad Dermatol. 2014 Feb.

Abstract

Atopic dermatitis (AD) is a chronic, pruritic, inflammatory dermatosis that affects up to 25% of children and 2% to 3% of adults. This guideline addresses important clinical questions that arise in the management and care of AD, providing updated and expanded recommendations based on the available evidence. In this first of 4 sections, methods for the diagnosis and monitoring of disease, outcomes measures for assessment, and common clinical associations that affect patients with AD are discussed. Known risk factors for the development of disease are also reviewed.

Keywords: AAD; AD; ADHD; American Academy of Dermatology; CDLQI; Children's Dermatology Life Quality Index; DFI; DLQI; Dermatitis Family Impact; Dermatology Life Quality Index; EASI; Eczema Area and Severity Index; FLG; GREAT; Global Resource for Eczema Trials; IGA; IL; ISAAC; IgE; International Study of Asthma and Allergies in Childhood; Investigator's Global Assessment; MDC; POEM; Patient-Oriented Eczema Measure; SASSAD; SCORAD; SCORing Atopic Dermatitis; SORT; Six Area, Six Sign Atopic Dermatitis; TARC; TISS; Three-Item Severity Scale; UK; United Kingdom; assessment scales; atopic dermatitis; attention deficit hyperactivity disorder; biomarkers; clinical associations; criteria; diagnosis; filaggrin; immunoglobulin E; interleukin; macrophage-derived chemoattractant; risk factors; strength of recommendation taxonomy; thymus and activation-regulated chemokine.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Nankervis H, Maplethorpe A, Williams HC. Mapping randomized controlled trials of treatments for eczema--the GREAT database (the Global Resource of EczemA Trials: a collection of key data on randomized controlled trials of treatments for eczema from 2000 to 2010) BMC dermatology. 2011;11:10. - PMC - PubMed
    1. Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR, Margolis DJ, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association “Administrative Regulations for Evidence-Based Clinical Practice Guidelines”. J Am Acad Dermatol. 2004;50:391–404. - PubMed
    1. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol. 2012;26:1176–1193. - PubMed
    1. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26:1045–1060. - PubMed
    1. Schneider L, Tilles S, Lio P, Boguniewicz M, Beck L, LeBovidge J, et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol. 2013;131:295–299. e1–27. - PubMed

Publication types

MeSH terms